No profile data available.
DBV Technologies S.a. (DBVT) is a healthcare company in the allergy treatment pharmaceuticals industry, based in Châtillon, France, with about 170 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$146.95 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $615.92 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.
DBV Technologies reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$615.92 million as of October 9, 2026.
Listed companies of a similar size in the same industry (allergy treatment pharmaceuticals) include Rapt Therapeutics, Inc. (RAPT), ARS Pharmaceuticals, Inc. (SPRY), Nasus Pharma Ltd. (NSRX).